P
US9375482B2ExpiredUtilityPatentIndex 48

Polylactide compositions and uses thereof

Assignee: UNIV GENEVEPriority: Apr 22, 2005Filed: Apr 22, 2014Granted: Jun 28, 2016
Est. expiryApr 22, 2025(expired)· nominal 20-yr term from priority
Inventors:MOLLER MICHAELTRIMAILLE THOMASGURNY ROBERT
A61P 31/04A61P 31/00C08G 63/823C08G 63/08A61K 9/1075A61K 9/0024A61K 31/65A61K 47/34A61K 9/0019
48
PatentIndex Score
0
Cited by
60
References
31
Claims

Abstract

The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A pharmaceutical composition comprising a polylactide and a drug, wherein the polylactide has the structure: 
       
         
           
           
               
               
           
         
         wherein:
 R 1 , R 2 , R 3 , and R 4  are each independently chosen from the group consisting of unsubstituted C 1-20 alkyl, hydrogen, C 2-20 alkenyl, and —(CH 2 ) y —(C 6 H 5 ), wherein y=1-20; 
 n is 2 to 100; 
 X is hydrogen or —C(O)—CH═CH 2 ; 
 at least one of R 1 , R 2 , R 3 , and R 4  is C 4-20  unsubstituted alkyl, C 2-20  alkenyl, or —(CH 2 ) y —(C 6 H 5 ), wherein y=1-20; 
 Y is —O—(CH 2 —CH 2 —O) p —CH 3 , wherein p is 1 to 700; 
 and wherein the polylactide has a T g  value of less than 15° C. 
 
       
     
     
       2. The composition of  claim 1 , wherein the pharmaceutical composition is formulated for parenteral, oral, topical, buccal, rectal, sublingual, intravenous, intradermal, transdermal, intrathecal, intraarterial, intraperitoneal, intranasal, mucosal, intravaginal, intrarectal, intramuscular, inhalation, injection, infusion, subcutaneous, or topical administration. 
     
     
       3. The composition of  claim 2 , wherein the pharmaceutical composition is formulated for buccal, mucosal, intravaginal, or intrarectal administration. 
     
     
       4. The composition of  claim 2 , wherein the pharmaceutical composition is formulated for topical administration. 
     
     
       5. The composition of  claim 4 , wherein the pharmaceutical composition is formulated as an ointment, paste, or cream. 
     
     
       6. The composition of  claim 2 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
       7. The composition of  claim 2 , wherein the pharmaceutical composition is formulated as a powder or a tablet. 
     
     
       8. The composition of  claim 1 , wherein the pharmaceutical composition is formulated as eye drops. 
     
     
       9. The composition of  claim 1 , wherein the pharmaceutical composition is formulated for inhalation or other aerosol delivery. 
     
     
       10. The composition of  claim 1 , wherein n is 2 to 75. 
     
     
       11. The composition of  claim 10 , wherein n is 2 to 50. 
     
     
       12. The composition of  claim 11 , wherein p is 1 to 250. 
     
     
       13. The composition of  claim 10 , wherein R 1  and R 3  are hydrogen; and R 2  and R 4  are C 4-20  alkyl. 
     
     
       14. The composition of  claim 13 , wherein R 2  and R 4  are —(CH 2 ) m —CH 3 , wherein m is from 3-19. 
     
     
       15. The composition of  claim 14 , wherein m is from 3 to 12. 
     
     
       16. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) m —CH 3  or —CH 3 , wherein m=3-12. 
     
     
       17. The composition of  claim 16 , wherein m=3-9. 
     
     
       18. The composition of  claim 1 , wherein m=4-6. 
     
     
       19. The composition of  claim 1 , wherein m=5. 
     
     
       20. The composition of  claim 11 , wherein n is 2 to 25. 
     
     
       21. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) m —CH 3 , wherein m=3-12. 
     
     
       22. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —CH 2 —(C 6 H 5 ) or —CH 3 . 
     
     
       23. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —CH 2 —(C 6 H 5 ). 
     
     
       24. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —CH(CH 3 ) 2  or —CH 3 . 
     
     
       25. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) 3 —CH 3  or —CH 3 . 
     
     
       26. The composition of  claim 1 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) 5 —CH 3  or —CH 3 . 
     
     
       27. The composition of  claim 26 , wherein the pharmaceutical composition is formulated for topical administration, rectal administration, intranasal administration, oral administration, or the composition is formulated as eye drops. 
     
     
       28. The composition of  claim 27 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) 5 —CH 3  or —CH 3 . 
     
     
       29. The composition of  claim 27 , wherein R 1  and R 3  are hydrogen; and wherein R 2  and R 4  are —(CH 2 ) 5 —CH 3 . 
     
     
       30. The composition of  claim 29 , wherein the composition is formulated for topical administration. 
     
     
       31. The composition of  claim 29 , wherein the composition is formulated as eye drops.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.